CY1107937T1 - Προφαρμακα σε συνδετες υποδοχεα nmda - Google Patents

Προφαρμακα σε συνδετες υποδοχεα nmda

Info

Publication number
CY1107937T1
CY1107937T1 CY20081100485T CY081100485T CY1107937T1 CY 1107937 T1 CY1107937 T1 CY 1107937T1 CY 20081100485 T CY20081100485 T CY 20081100485T CY 081100485 T CY081100485 T CY 081100485T CY 1107937 T1 CY1107937 T1 CY 1107937T1
Authority
CY
Cyprus
Prior art keywords
nmda
connectors
products
compounds
lower alkyl
Prior art date
Application number
CY20081100485T
Other languages
Greek (el)
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fisher
Neidhart Marie-Paule Heitz
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1107937T1 publication Critical patent/CY1107937T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20081100485T 2000-08-21 2008-05-08 Προφαρμακα σε συνδετες υποδοχεα nmda CY1107937T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
EP01965201A EP1313703B1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (1)

Publication Number Publication Date
CY1107937T1 true CY1107937T1 (el) 2013-09-04

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100485T CY1107937T1 (el) 2000-08-21 2008-05-08 Προφαρμακα σε συνδετες υποδοχεα nmda

Country Status (35)

Country Link
US (1) US6407235B1 (enExample)
EP (1) EP1313703B1 (enExample)
JP (1) JP4162991B2 (enExample)
KR (1) KR100589991B1 (enExample)
CN (1) CN1227230C (enExample)
AR (1) AR030373A1 (enExample)
AT (1) ATE386022T1 (enExample)
AU (2) AU2001285894B2 (enExample)
BR (1) BR0113348A (enExample)
CA (1) CA2419279C (enExample)
CY (1) CY1107937T1 (enExample)
CZ (1) CZ303319B6 (enExample)
DE (1) DE60132782T2 (enExample)
DK (1) DK1313703T3 (enExample)
EC (1) ECSP034489A (enExample)
EG (1) EG24293A (enExample)
ES (1) ES2299508T3 (enExample)
HR (1) HRP20030125B1 (enExample)
HU (1) HU229802B1 (enExample)
IL (1) IL154254A0 (enExample)
JO (1) JO2289B1 (enExample)
MA (1) MA26947A1 (enExample)
MX (1) MXPA03001311A (enExample)
MY (1) MY136065A (enExample)
NO (1) NO324941B1 (enExample)
NZ (1) NZ523990A (enExample)
PA (1) PA8525601A1 (enExample)
PE (1) PE20020291A1 (enExample)
PL (1) PL204215B1 (enExample)
PT (1) PT1313703E (enExample)
RS (1) RS51467B (enExample)
RU (1) RU2272027C2 (enExample)
SI (1) SI1313703T1 (enExample)
WO (1) WO2002016321A1 (enExample)
ZA (1) ZA200300894B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300235A2 (hu) * 2000-03-21 2003-08-28 The Procter & Gamble Co. Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US8759400B2 (en) * 2005-12-19 2014-06-24 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
CN105683180B (zh) 2013-11-05 2020-01-21 阿斯利康(瑞典)有限公司 Nmda拮抗剂前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420053T2 (de) * 1994-01-31 1999-11-25 Pfizer Inc., New York Neuroprotektive chroman verbindungen
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
ZA200300894B (en) 2004-04-30
BR0113348A (pt) 2003-07-08
JP2004506715A (ja) 2004-03-04
PL204215B1 (pl) 2009-12-31
ECSP034489A (es) 2003-03-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
HRP20030125A2 (en) 2005-02-28
IL154254A0 (en) 2003-09-17
MY136065A (en) 2008-08-29
CZ2003492A3 (cs) 2004-01-14
EP1313703A1 (en) 2003-05-28
JP4162991B2 (ja) 2008-10-08
ES2299508T3 (es) 2008-06-01
CA2419279C (en) 2008-10-14
DK1313703T3 (da) 2008-05-19
DE60132782D1 (de) 2008-03-27
HUP0301548A2 (hu) 2003-08-28
AR030373A1 (es) 2003-08-20
DE60132782T2 (de) 2009-02-05
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
CZ303319B6 (cs) 2012-08-01
KR100589991B1 (ko) 2006-06-15
NZ523990A (en) 2004-09-24
KR20030022417A (ko) 2003-03-15
JO2289B1 (en) 2005-09-12
PA8525601A1 (es) 2002-04-25
AU2001285894B2 (en) 2006-06-15
PE20020291A1 (es) 2002-04-17
CN1447793A (zh) 2003-10-08
CA2419279A1 (en) 2002-02-28
US6407235B1 (en) 2002-06-18
RU2272027C2 (ru) 2006-03-20
EP1313703B1 (en) 2008-02-13
MA26947A1 (fr) 2004-12-20
NO20030781L (no) 2003-02-19
NO20030781D0 (no) 2003-02-19
ATE386022T1 (de) 2008-03-15
US20020040037A1 (en) 2002-04-04
SI1313703T1 (sl) 2008-06-30
MXPA03001311A (es) 2003-06-30
AU8589401A (en) 2002-03-04
HRP20030125B1 (en) 2011-07-31
WO2002016321A1 (en) 2002-02-28
HUP0301548A3 (en) 2010-03-29
PL361387A1 (en) 2004-10-04
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28

Similar Documents

Publication Publication Date Title
DK1485359T3 (da) Natriumkanalblokkere
BR0314227A (pt) Derivados de amido de hidroxialquila
CY1107937T1 (el) Προφαρμακα σε συνδετες υποδοχεα nmda
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
CY1108481T1 (el) Ενωσεις 2,3-διϋδρο-6-νιτροϊμιδαζο[2,1-β]οξαζολιου για τη θεραπεια φυματιωσης
CY1109220T1 (el) Παραγωγα ν-ακυλαμινοβενζολιου ως εκλεκτικοι αναστολεις της οξειδασης μονοαμινης β
DK633088A (da) Kollagenaseinhibitorer
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
FI101301B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi
IT1275997B1 (it) Enammine come accelleranti di vulcanizzazione per gomme naturali o sintetiche
CO5650218A2 (es) Composiciones de enjuague bucal que contienen sales del alquil ester de n-acil arginina
UA40573C2 (uk) Похідні 2-ціано-3-гідроксипропенаміду, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
CY1105786T1 (el) Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα
AR019197A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA ANTIHISTAMINICOS, COMPUESTOS INTERMEDIOS, PROCEDIMIENTO DE PREPARACIoN DE DERIVADOS DE PIPERIDINA Y PROCEDIMIENTOS DE PREPARACIoN DE INTERMEDIARIOS.
ITMI913400A1 (it) Acidi triazinilfosfonici e loro impiego in composizioni polimeriche autoestinguenti.
DE69405439D1 (de) Verfahren zur Herstellung von Aminotriazin-Derivaten
ATE6500T1 (de) 2-alpha-methyl-dopaminimino-6,7-dihydroxy-1,2,3 4-tetrahydronaphthalin, seine salze, und verfahren zu dessen herstellung.
DE69527854D1 (de) Derivate substituierter amidinonaphthylester
GR930100500A (el) Παράγωγα φαινυλοξικού οξέως, διεργασία για την παρασκευή τους και αντίστοιχη χρήση.
IL150100A0 (en) Pharmaceutical compositions containing fused cyclic compounds
CY1105422T1 (el) Νεα πιπepιδινυλο-αλκυλαμινο-πυριδαζινονικα παραγωγα, μια διαδικασια για την παρασκευη τους και φαρμακευτικες συνθεσεις οι οποιες πepιεχουν τις εν λογω ενωσεις
FR2794122B1 (fr) Nouveaux antioxydants, procedes de preparation et utilisations
DE69904940D1 (de) 6-deoxy-erythromycin-derivate, ihrer herstellung, und ihrer verwendung als arzneimitteln
FR2609464B1 (fr) Nouveaux derives du n-(1h-indol 4-yl) benzamide ainsi que leurs sels, leur application a titre de medicaments, et les compositions les renfermant